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ermatofibrosarcoma protuberans (DFSP) is
a rare soft-tissue neoplasm in children with
low-grade malignant potential; metastasis is
rare but there is risk of local recurrence after
treatment.1 An adequate surgical tumor-free margin
is vital for long-term outcome and survival after wide
excision or Mohs micrographic surgery.1 However,
such surgeries may result in severe functional and
cosmetic defects at anatomically critical areas.
Neoadjuvant or adjuvant imatinib mesylate therapy
may help control tumor progression, but treatment
experience in pediatricDFSP is limited to case reports
and there is no established treatment protocol. We
report a toddler boy with a DFSP near his left eye
treated with adjuvant imatinib mesylate after an
inadequate postoperative tumor-free margin.
CASE REPORT
A 22-month-old Taiwanese boy presented with an
asymptomatic bluish nodule measuring 0.63 0.4 cm
over the nasal root near the left medial canthus. Not
present at birth, the nodule was first noted by
his parents when he was 11 months old with
discoloration but no discomfort was reported.
Infantile hemangioma was diagnosed and regular
follow-up advised. The tumor grew to 1.0 3 0.6 cm
in the following 8 months (Fig 1, A) and he was
referred to a plastic surgeon for tumor excision.
Histopathology revealed Bednar tumor, a pigmented
variant of DFSP. An adequate tumor-free margin
(2-4 cm) without mutilation was impossible becausethe Department of Dermatology,a Section of Plastic and
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subsequently received a wider tumor excision and
reconstruction with cheek flap advancement. The
re-excision margin was designed to be 2 to 3 mm
around the initial excision scar and 1 mm near the
nasal side wall for preservation of the nasal
canaliculi. The final histopathological postoperative
tumor-free margins were 1 mm peripherally around
the tumor and 3 mm deep. Postoperative radiation
therapy was not recommended because it could
affect normal bone growth and lead to face defor-
mity. Treatment was started with imatinib mesylate, a
tyrosine kinase inhibitor, at a dose of 430 mg/m2/d.
The dose was tapered to 280 mg/m2/d 4 weeks later
because of poor appetite. No other significant side
effects were noted. Six months and 20 months after
initiating imatinib, magnetic resonance images of the
head revealed no evidence of recurrence. He
received imatinib daily for a total of 18 months and
remained disease free at 23 months’ follow-up.
Physical examination revealed a soft, healing
surgical scar without any signs of local recurrence
(Fig 1, B).
DISCUSSION
Early diagnosis of pediatric DFSP is critical to
minimize surgical disfiguration. However, definite
diagnosis is usually difficult in neonates or infants
with congenital DFSP because of its diverse presen-
tation in childhood. The tumor may clinically mimic a
vascular birthmark, vascular tumor, morphea, aHospital, 138 Sheng-Li Road, Tainan, Taiwan 704. E-mail:
twwong@mail.ncku.edu.tw.
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Fig 1. A bluish tumor located on the left medial canthus region in a 22-month-old boy that was
proved as dermatofibrosarcoma protuberans histopathologically. A, Even a minimal 2-cm
surgical tumor-free margin (dashed line) would result in severe disfigurement. B, There was no
tumor recurrence at 23 months’ follow-up with 18 months of adjuvant daily oral imatinib, a
tyrosine kinase inhibitor.
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stages.2 A histopathological tumor-free surgical
margin is the most important prognostic factor
in patients with DFSP. In a series of 159 patients,
local recurrence ratewas 18% in patients with positive
or close (\1 mm) margins versus 3% in patients
with negative margins at a median follow-up
of 57 months.3 According to the National Com-
prehensive Cancer Network guideline, resection
with 2- to 4-cm margins to the depth of muscular
fascia or pericranium is recommended when clini-
cally feasible, although some experts recommend 1-
to 2-cm margins in children younger than 5 years.4,5
The overall prognosis of pediatric DFSP is excellent
with adequate free surgical margin. Of the 166 cases
reported with available follow-up data, only 1 patient
died of aggressive local recurrence.5 Nevertheless,
without adjuvant therapy the 1-mm tumor-free
margin near the eye poses a theoretical local recur-
rence rate of 3% to 18% in our case.
Most pediatric DFSPs, like their adult counter-
parts, are characterized by a distinctive gene
rearrangement that fuses collagen type Ia1 chain
gene of chromosome 17 with platelet-derived
growth factor b-chain gene (PDGFB) of chromo-
some 22, up-regulating the PDGFB receptor tyrosine
kinase and stimulating tumor growth and malignant
transformation.6 Imatinib mesylate, an adenosine
triphosphate analog, competitively inhibits the bind-
ing site of the PDGFB receptor.6 Although imatinibhas been demonstrated to achieve a response in 65%
of reported adult cases, its effectiveness in pediatric
DFSP remains in the investigational phase because of
limited studies.7 Only 5 cases have been reported
(Table I) in the English-language literature.
Nevertheless, initial results are encouraging,
although doses and duration of therapy have not
been standardized. Polymerase chain reaction has
been used for molecular diagnosis in DFSP, and
although polymerase chain reaction was not per-
formed in our patient, the collagen type Ia1 chain
gene-PDGFB fusion was assumed to be positive in
this case given the 100% positive rate reported in
another study using sensitive multiplex reverse
transcription polymerase chain reaction screening
of DFSP.8 Gooskens et al5 suggested using this
molecular marker as a guide for postoperative
imatinib therapy decision-making to assure contin-
uous remission. In their case series, they found gene
fusion in all 3 resected pediatric DFSP tumor tissues
that had been treated with neoadjuvant imatinib.
Adjuvant imatinib was initiated in 2 patients with
positive molecular marker at resection margin
despite complete histologic remission. The remain-
ing patient with histologic and molecular tumor-free
resection margins was not treated with adjuvant
imatinib and stayed clinically free of disease at
3 years’ follow-up. Based on this observation, we
recommend molecular analysis of resection margins
in all pediatric DFSP cases if available. Nevertheless,
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174 Yen et althe clinical value of minimal residual molecular
disease in DFSP needs further evaluation by larger
studies.
We emphasize early biopsy of a lesion suspicious
for DFSP in children. When the lesion is unresectable
or tumor-free margins positive or suboptimal, imati-
nib mesylate is a viable target neoadjuvant or
adjuvant therapy. Our case suggests that postopera-
tive imatinib mesylate may achieve tumor remission
with minimal side effects.
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